Petra Financial Advisors Inc. increased its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 1.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,004 shares of the exchange traded fund’s stock after purchasing an additional 152 shares during the quarter. Petra Financial Advisors Inc.’s holdings in SPDR S&P Biotech ETF were worth $890,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Fifth Third Bancorp boosted its stake in shares of SPDR S&P Biotech ETF by 3.4% during the 2nd quarter. Fifth Third Bancorp now owns 118,303 shares of the exchange traded fund’s stock worth $10,968,000 after buying an additional 3,922 shares during the last quarter. Avantax Advisory Services Inc. boosted its position in SPDR S&P Biotech ETF by 17.2% during the first quarter. Avantax Advisory Services Inc. now owns 9,619 shares of the exchange traded fund’s stock valued at $913,000 after purchasing an additional 1,415 shares during the last quarter. PFG Investments LLC grew its stake in SPDR S&P Biotech ETF by 9.2% in the second quarter. PFG Investments LLC now owns 24,844 shares of the exchange traded fund’s stock valued at $2,303,000 after purchasing an additional 2,097 shares in the last quarter. Brookstone Capital Management bought a new position in shares of SPDR S&P Biotech ETF in the first quarter valued at $284,000. Finally, Sequoia Financial Advisors LLC lifted its stake in SPDR S&P Biotech ETF by 14.1% in the first quarter. Sequoia Financial Advisors LLC now owns 6,810 shares of the exchange traded fund’s stock valued at $646,000 after acquiring an additional 842 shares during the last quarter.
SPDR S&P Biotech ETF Trading Down 0.6 %
Shares of SPDR S&P Biotech ETF stock traded down $0.58 during trading on Thursday, hitting $97.84. 1,414,091 shares of the stock were exchanged, compared to its average volume of 9,314,223. SPDR S&P Biotech ETF has a 1-year low of $63.80 and a 1-year high of $103.52. The stock has a market capitalization of $7.46 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. The company has a fifty day moving average price of $98.99 and a 200-day moving average price of $94.80.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Articles
- Five stocks we like better than SPDR S&P Biotech ETF
- How to Effectively Use the MarketBeat Ratings Screener
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Stock Market Upgrades: What Are They?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
- Health Care Stocks Explained: Why You Might Want to Invest
- Caterpillar Stock: Market Points to a Buying Opportunity
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.